Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment

被引：3

作者：

Primorac, Dragan ^{[1
,2
,3
,4
,5
,6
,7
,8
]}

Cemerin, Martin ^{[9
]}

Matisic, Vid ^{[1
]}

Molnar, Vilim ^{[1
]}

Strbad, Marko ^{[10
,11
]}

Girandon, Lenart ^{[10
]}

Zenic, Lucija ^{[12
]}

Knezevic, Miomir ^{[10
]}

Minger, Stephen ^{[13
]}

Polancec, Denis ^{[12
]}

机构：

[1] St Catherine Specialty Hosp, Zagreb 10000, Croatia

[2] Penn State Univ, Eberly Coll Sci, Univ Pk, State Coll, PA 16802 USA

[3] Univ New Haven, Henry C Lee Coll Criminal Justice & Forens Sci, West Haven, CT 06516 USA

[4] Univ Split, Med Sch, Split 21000, Croatia

[5] Josip Juraj Strossmayer Univ Osijek, Fac Dent Med & Hlth, Osijek 31000, Croatia

[6] Josip Juraj Strossmayer Univ Osijek, Fac Med, Osijek 31000, Croatia

[7] Univ Rijeka, Fac Med, Rijeka 51000, Croatia

[8] Med Sch REGIOMED, D-96450 Coburg, Germany

[9] Univ Zagreb, Sch Med, Zagreb 10000, Croatia

[10] Educell Ltd, Trzin 1236, Slovenia

[11] Biobanka Ltd, Trzin 1236, Slovenia

[12] Srebrnjak Childrens Hosp, Zagreb 10000, Croatia

[13] Natl Inst Biol, Ljubljana 1000, Slovenia

来源：

PHARMACEUTICS | 2021年 / 13卷 / 09期

关键词：

COVID-19; mesenchymal stromal cells; MSCs; immunomodulation; ARDS; UMBILICAL-CORD BLOOD; VERSUS-HOST-DISEASE; STEM-CELLS; BONE-MARROW; CYTOKINE STORM; FUNCTIONAL RECEPTOR; CORONAVIRUS; PATIENT;

D O I：

10.3390/pharmaceutics13091481

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.

引用

页数：14

共 103 条

[1] Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) [J].

Ahn, Dae-Gyun ;

Shin, Hye-Jin ;

Kim, Mi-Hwa ;

Lee, Sunhee ;

Kim, Hae-Soo ;

Myoung, Jinjong ;

Kim, Bum-Tae ;

Kim, Seong-Jun .

JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2020, 30 (03) :313-324

[2] Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials [J].

Al-Abdouh, Ahmad ;

Bizanti, Anas ;

Barbarawi, Mahmoud ;

Jabri, Ahmad ;

Kumar, Ashish ;

Fashanu, Oluwaseun E. ;

Khan, Safi U. ;

Zhao, Di ;

Antar, Annukka A. R. ;

Michos, Erin D. .

CONTEMPORARY CLINICAL TRIALS, 2021, 101

[3] Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies [J].

Alcayaga-Miranda, Francisca ;

Cuenca, Jimena ;

Khoury, Maroun .

FRONTIERS IN IMMUNOLOGY, 2017, 8

[4] Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis [J].

Alene, Muluneh ;

Yismaw, Leltework ;

Assemie, Moges Agazhe ;

Ketema, Daniel Bekele ;

Mengist, Belayneh ;

Kassie, Bekalu ;

Birhan, Tilahun Yemanu .

PLOS ONE, 2021, 16 (03)

[5] Roles of Mesenchymal Stem Cells in Tissue Regeneration and Immunomodulation [J].

Ayala-Cuellar, Ana Patricia ;

Kang, Ji-Houn ;

Jeung, Eui-Bae ;

Choi, Kyung-Chul .

BIOMOLECULES & THERAPEUTICS, 2019, 27 (01) :25-33

[6] Remdesivir for the Treatment of Covid-19-Final Report [J].

Beigel, John H. ;

Tomashek, Kay M. ;

Dodd, Lori E. ;

Mehta, Aneesh K. ;

Zingman, Barry S. ;

Kalil, Andre C. ;

Hohmann, Elizabeth ;

Chu, Helen Y. ;

Luetkemeyer, Annie ;

Kline, Susan ;

de Castilla, Diego Lopez ;

Finberg, Robert W. ;

Dierberg, Kerry ;

Tapson, Victor ;

Hsieh, Lanny ;

Patterson, Thomas F. ;

Paredes, Roger ;

Sweeney, Daniel A. ;

Short, William R. ;

Touloumi, Giota ;

Lye, David Chien ;

Ohmagari, Norio ;

Oh, Myoung-don ;

Ruiz-Palacios, Guillermo M. ;

Benfield, Thomas ;

Faetkenheuer, Gerd ;

Kortepeter, Mark G. ;

Atmar, Robert L. ;

Creech, C. Buddy ;

Lundgren, Jens ;

Babiker, Abdel G. ;

Pett, Sarah ;

Neaton, James D. ;

Burgess, Timothy H. ;

Bonnett, Tyler ;

Green, Michelle ;

Makowski, Mat ;

Osinusi, Anu ;

Nayak, Seema ;

Lane, H. Clifford .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (19) :1813-1826

[7]

Bieback Karen, 2007, Curr Stem Cell Res Ther, V2, P310, DOI 10.2174/157488807782793763

[8]

Bonus BioGroup Ltd, MESENCURE

[9] Mesenchymal Stem Cells and Pericytes: To What Extent Are They Related? [J].

Botelho de Souza, Lucas Eduardo ;

Malta, Tathiane Maistro ;

Haddad, Simone Kashima ;

Covas, Dimas Tadeu .

STEM CELLS AND DEVELOPMENT, 2016, 25 (24) :1843-1852

[10] Angiotensin-converting enzyme 2 (ACE2),SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) [J].

Bourgonje, Arno R. ;

Abdulle, Amaal E. ;

Timens, Wim ;

Hillebrands, Jan-Luuk ;

Navis, Gerjan J. ;

Gordijn, Sanne J. ;

Bolling, Marieke C. ;

Dijkstra, Gerard ;

Voors, Adriaan A. ;

Osterhaus, Albert D. M. E. ;

van Der Voort, Peter H. J. ;

Mulder, Douwe J. ;

van Goor, Harry .

JOURNAL OF PATHOLOGY, 2020, 251 (03) :228-248

← 1 2 3 4 5 6 7 8 9 10 →